Len Alexander Pennacchio from 3185 Mariola Rd, Sebastopol, CA 95472, age 54, Phone: (707)8236002

Us Patents

Apolipoprotein Gene Involved In Lipid Metabolism
view source
US Patent:

7238475, Jul 3, 2007
Filed:

Aug 27, 2002
Appl. No.:

10/229834
Inventors:

Edward Rubin - Berkeley CA, US
Len A. Pennacchio - Sebastopol CA, US
Assignee:

The Regents of The University of California - Oakland CA
International Classification:

C12Q 1/68
C12P 19/34
C07H 21/04
US Classification:

435 6, 435 912, 536 243, 536 2431
Abstract:

Methods and materials for studying the effects of a newly identified human gene, APOAV, and the corresponding mouse gene apoAV. The sequences of the genes are given, and transgenic animals which either contain the gene or have the endogenous gene knocked out are described. In addition, single nucleotide polymorphisms (SNPs) in the gene are described and characterized. It is demonstrated that certain SNPs are associated with diseases involving lipids and triglycerides and other metabolic diseases. These SNPs may be used alone or with SNPs from other genes to study individual risk factors. Methods for intervention in lipid diseases, including the screening of drugs to treat lipid-related or diabetic diseases are also disclosed.

Novel Apolipoprotein Gene Involved In Lipid Metabolism
view source
US Patent:

20090181884, Jul 16, 2009
Filed:

May 29, 2007
Appl. No.:

11/807788
Inventors:

Edward Rubin - Berkeley CA, US
Len A. Pennacchio - Sebastopol CA, US
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

A61K 38/17
C07K 14/775
C07K 16/18
C07H 21/04
A61P 3/00
US Classification:

514 12, 530359, 5303879, 536 235
Abstract:

Methods and materials for studying the effects of a newly identified human gene, APOAV, and the corresponding mouse gene apoAV. The sequences of the genes are given, and transgenic animals which either contain the gene or have the endogenous gene knocked out are described. In addition, single nucleotide polymorphisms (SNPs) in the gene are described and characterized. It is demonstrated that certain SNPs are associated with diseases involving lipids and triglycerides and other metabolic diseases. These SNPs may be used alone or with SNPs from other genes to study individual risk factors. Methods for intervention in lipid diseases, including the screening of drugs to treat lipid-related or diabetic diseases are also disclosed.

Long-Range Barcode Labeling-Sequencing
view source
US Patent:

20130130919, May 23, 2013
Filed:

Oct 16, 2012
Appl. No.:

13/653343
Inventors:

The Regents of the University of California - Oakland CA, US
Tao Zhang - San Diego CA, US
Kanwar K. Singh - Pittsburg CA, US
Len A. Pennacchio - Sebastopol CA, US
Jeff L. Froula - Walnut Creek CA, US
Kevin S. Eng - San Francisco CA, US
Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:

C12Q 1/68
US Classification:

506 2
Abstract:

Methods for sequencing single large DNA molecules by clonal multiple displacement amplification using barcoded primers. Sequences are binned based on barcode sequences and sequenced using a microdroplet-based method for sequencing large polynucleotide templates to enable assembly of haplotype-resolved complex genomes and metagenomes.

Cystatin B Mutants
view source
US Patent:

6432635, Aug 13, 2002
Filed:

Mar 18, 1997
Appl. No.:

08/819872
Inventors:

Richard M. Myers - Stanford CA
David R. Cox - Belmont CA
Len A. Pennacchio - Menlo Park CA
Anna-Elina Lehesjoki - Espoo, FI
Albert De La Chapelle - Helsingfors, FI
Assignee:

Helsinki University Licensing Ltd. Oy - Helsinki
The Board of Trustees of the Leland Stanford Jr. Univeristy - Stanford CA
International Classification:

C12Q 168
US Classification:

435 6, 435810, 436501, 935 23, 935 78, 935 88, 536 27
Abstract:

An isolated nucleic acid molecule, wherein the molecule contains: (1) a first sequence consisting of human cystatin B genomic DNA as set forth in FIG. 3 (SEQ ID NO:1); (2) a second sequence, wherein said second sequence is a subsequence of said first sequence, is at least nucleotides in length, and is not present in human cystatin B cDNA; (3) a third sequence in which at least one nucleotide of said first or second sequences is replaced by a different nucleotide; or (4) a fourth sequence complementary to any of said first, second or third sequences; with the proviso that (I) if said molecule is an RNA molecule, U replaces T in said sequence of said molecule, and (ii) said third sequence is at least 95% identical to said first or second sequence.

Method Of Treating A Diarrhea Disorder Using A Novel Polypeptide
view source
US Patent:

20200087360, Mar 19, 2020
Filed:

May 22, 2019
Appl. No.:

16/419860
Inventors:

- Oakland CA, US
Len A. Pennacchio - Sebastopol CA, US
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

C07K 14/435
C12N 15/86
Abstract:

The present invention provides for a recombinant or isolated polypeptide comprising the amino acid sequence of an enhancer polypeptide associated with a diarrhea disorder; a transgenic non-human mammal, wherein the mammal is deleted or knocked out for one or more of an intestine-critical region (ICR); a pharmaceutical composition comprising the polypeptide of the present invention and a pharmaceutical acceptable carrier; and, a method of treating or preventing a subject suffering or at risk or suspected of suffering from a diarrhea disease or disorder, the method comprising administrating a pharmaceutical composition of the present invention to a subject in need of such treatment.

Brain-Specific Enhancers For Cell-Based Therapy
view source
US Patent:

20150044187, Feb 12, 2015
Filed:

Oct 10, 2014
Appl. No.:

14/512306
Inventors:

Axel Visel - El Cerrito CA, US
John L.R. Rubenstein - San Francisco CA, US
Len A. Pennacchio - Sebastopol CA, US
Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:

G01N 33/569
C12N 15/85
G01N 33/50
A61K 35/54
US Classification:

424 937, 536 241, 4353201, 4352523, 435 34, 43525411, 435419, 435325, 435 71
Abstract:

Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyses. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.

Compositions And Methods For Detecting Noonan Syndrome
view source
US Patent:

20150017649, Jan 15, 2015
Filed:

Jun 20, 2014
Appl. No.:

14/310177
Inventors:

- New York NY, US
- Oakland CA, US
Len Pennacchio - Walnut Creek CA, US
Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
MOUNT SINAI SCHOOL OF MEDICINE - New York NY
International Classification:

C12Q 1/68
US Classification:

435 612, 435 618
Abstract:

Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAFl or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.

Wikipedia

Len A. Pennacchio

view source

Len A. Pennacchio is an American molecular biologist, the head of the Genetic Analysis Program and the Genomic Technologies Program at the Joint Genome ...